- Home
- OPRX
as 10-04-2024 4:00pm EST
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 149.5M | IPO Year: | N/A |
| Target Price: | $13.50 | AVG Volume (30 days): | 116.5K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.84 - $16.65 | Next Earning Date: | 11-04-2024 |
| Revenue: | $83,202,506 | Revenue Growth: | 35.15% |
| Revenue Growth (this year): | 43.61% | Revenue Growth (next year): | 12.92% |
Latest OptimizeRx Corporation News
OPRX Breaking Stock News: Dive into OPRX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
GlobeNewswire
25 days ago
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
MT Newswires
a month ago
OptimizeRx Launches AI-Driven Product for Health Sector Marketers
GlobeNewswire
a month ago
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
Zacks
a month ago
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
MT Newswires
2 months ago
RBC Adjusts OptimizeRx's PT to $14 From $17, Maintains Outperform Rating
Simply Wall St.
2 months ago
Earnings Release: Here's Why Analysts Cut Their OptimizeRx Corporation (NASDAQ:OPRX) Price Target To US$15.79
Simply Wall St.
2 months ago
OptimizeRx Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Compare OPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPRX OptimizeRx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.